FINAL DATA FROM THE PHASE 3 ALCANZA STUDY: BRENTUXIMAB VEDOTIN (BV) VS PHYSICIAN'S CHOICE (PC) IN PATIENTS (PTS) WITH CD30‐POSITIVE (CD30+) CUTANEOUS T‐CELL LYMPHOMA (CTCL). (12th June 2019)

• Record Type: Journal Article
• Authors: Horwitz, S.M.; Scarisbrick, J.; Prince, H.M.; Whittaker, S.; Duvic, M.; Kim, Y.H.; Quaglino, P.; Zinzani, P.L.; Bechter, O.; Eradat, H.; Pinter‐Brown, L.; Akilov, O.; Geskin, L.; Sanches, J.; Ortiz‐Romero, P.; Lisano, J.; Brown, L.; Palanca‐Wessels, M.C.; Gautam, A.; Bunn, V.; Little, M.; Dummer, R.
• Is Part Of: Hematological oncology. Volume 37(2019)Supplement 2
• Page Start: 286
• Page End: 288
• Publication Date: 2019-06-12
• Subjects: Hematological oncology -- Periodicals; Hematology; Medical Oncology; 616.99418005
• DOI: 10.1002/hon.96_2630
• Languages: English
• ISSNs: 0278-0232